Hypoglycemic Effect of Protein Extract from Siamese Momordica charantia in Alloxan-Induced Diabetic Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2003
Sirintorn Yibchok-anun; Sirichai Adisakwattana; Kanin Tantisuwat; Palida Sajjapitak; Sakkan Phakinpun
Department of Pharmacology, Faculty of Veterinary Sciences, Chulalongkorn University
Phayathai, Bangkok, Thailand

Objectives

The objective of this study was to investigate the hypoglycemic effect of protein extracts from Momordica charantia (Thai bitter gourd) in alloxan-induced diabetic dogs.

Materials & Methods

Ten dogs were randomly assigned into 2 groups with 5 dogs each; normal and diabetic groups. The diabetic dogs were induced using alloxan 60-80 mg/kg IV. Both normal and diabetic groups were subcutaneously injected with 10, 30 and 50 units/kg of protein extract from Momordica charantia (1.8 mg of the extract = 40 units). Blood samples were collected at 0, 0.5, 1, 2, 4 and 8 hours after injection for measuring plasma glucose and insulin level.

Results

The Momordica charantia extract at 10 and 30 units/kg did not significantly decrease blood glucose level in both normal and diabetic groups. However, the 50 units/kg of protein extract significantly decreased blood glucose level at 4 and 8 hours after injection in diabetic dogs, but not in normal dogs. In contrast, all concentrations used of this extract did not significantly alter plasma insulin level in both groups.

Conclusion

We concluded that the protein extract from Siamese Momordica charantia (50 units/kg) exerted a hypoglycemic effect on alloxan-induced diabetic dogs via mechanism that may not involve in insulin secretion.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Sirintorn Yibchok-anun
Department of Pharmacology, Faculty of Veterinary Sciences, Chulalongkorn University
Phayathai, Bangkok, Thailand


MAIN : Internal Medicine : Momordica charantia
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27